title: [The clinical analysis of atrial fibrillation of 1 310 in patients in Urumqi of China].
abstract: OBJECTIVE
  To investigate the clinical features and current therapy of atrial fibrillation (AF) of inpatients in Urumqi, China.
  
  
  METHODS
  The clinical data of inpatients diagnosed with AF from January, 2008 to December, 2012, in 12 hospitals in Urumqi were retrospectively analyzed.
  
  
  RESULTS
  Totally 1 310 AF inpatients were enrolled in this study with the age of (64.8 ± 3.3) years old and a men to women ratio of 1.39. Most patients were in age groups of 61-70 years (26.5%) and 71-80 years (27.6%). More patients with paroxysmal AF were at cardiac function class I-II (75.2%), while more patients with persistent AF were at cardiac function class III-IV (31.0%) (both P values < 0.05). The most common co-morbidities of AF were hypertension (49.2%), coronary heart disease (38.5%), diabetes mellitus (20.1%). Compared with patients of chronic AF, the patients of paroxysmal AF had higher success rates in amiodarone conversation and sinus rhythm maintenance after ablation (44.8% vs 29.9%, 87.5% vs 68.9%, P values < 0.05). Among the 1 310 inpatients, 992 patients (75.7%) received antithrombotic therapy. There were statistically significant differences in CHA2DS2 score and incidence rate of cerebral infarction among patients receiving aspirin, warfarin or rivaroxaban/other anticoagulation drugs [2(1, 3) vs 3(2, 4) vs 3(2, 5) and 6.3% vs 23.8% vs 30.2%, both P values < 0.05].
  
  
  CONCLUSIONS
  Our results of AF inpatients' age, gender, related disease distribution, AF types, incidence of stoke, therapeutic and epidemiological features are in accordance with the domestic and abroad reports.
authors.affiliation: Department of Cardiology, the First Affiliated Hospital of Xinjiang Medical University, Urumqi 830054, China.
authors.forename: Xiaohua
authors.initials: X
authors.lastname: Guo
authors.affiliation: Department of Cardiology, the First Affiliated Hospital of Xinjiang Medical University, Urumqi 830054, China.
authors.forename: Yu
authors.initials: Y
authors.lastname: Zhang
authors.affiliation: Department of Cardiology, the First Affiliated Hospital of Xinjiang Medical University, Urumqi 830054, China.
authors.forename: Guojun
authors.initials: G
authors.lastname: Xu
authors.affiliation: Department of Cardiology, the First Affiliated Hospital of Xinjiang Medical University, Urumqi 830054, China.
authors.forename: Xianhui
authors.initials: X
authors.lastname: Zhou
authors.affiliation: Department of Cardiology, the First Affiliated Hospital of Xinjiang Medical University, Urumqi 830054, China.
authors.forename: Lei
authors.initials: L
authors.lastname: Li
authors.affiliation: Department of Cardiology, the First Affiliated Hospital of Xinjiang Medical University, Urumqi 830054, China. Email: tangbaopeng@hotmail.com.
authors.forename: Baopeng
authors.initials: B
authors.lastname: Tang
mesh_terms: D000368:Aged; D000638:Amiodarone / Q000627:therapeutic use*; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D000925:Anticoagulants / Q000008:administration & dosage*; D001241:Aspirin / Q000008:administration & dosage; D001281:Atrial Fibrillation / Q000188:drug therapy / Q000453:epidemiology; D002681:China / Q000453:epidemiology; D015897:Comorbidity; D003920:Diabetes Mellitus / Q000453:epidemiology; D065427:Factor Xa Inhibitors / Q000008:administration & dosage; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D006973:Hypertension / Q000453:epidemiology; D015994:Incidence; D007297:Inpatients / Q000706:statistics & numerical data*; D008297:Male; D009025:Morpholines / Q000008:administration & dosage; D012189:Retrospective Studies; D000069552:Rivaroxaban; D020521:Stroke / Q000453:epidemiology; D013876:Thiophenes / Q000008:administration & dosage; D016896:Treatment Outcome; D014859:Warfarin / Q000008:administration & dosage
chemical_list: D000889:Anti-Arrhythmia Agents; D000925:Anticoagulants; D065427:Factor Xa Inhibitors; D005343:Fibrinolytic Agents; D009025:Morpholines; D013876:Thiophenes; D014859:Warfarin; D000069552:Rivaroxaban; D000638:Amiodarone; D001241:Aspirin